- Home
- KNDI vs CGTX Comparison
KNDI vs CGTX Comparison
Compare KNDI & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNDI
- CGTX
- Stock Information
- Founded
- KNDI 2002
- CGTX 2007
- Country
- KNDI China
- CGTX United States
- Employees
- KNDI N/A
- CGTX N/A
- Industry
- KNDI Auto Manufacturing
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- KNDI Consumer Discretionary
- CGTX Health Care
- Exchange
- KNDI Nasdaq
- CGTX Nasdaq
- Market Cap
- KNDI 109.2M
- CGTX 126.2M
- IPO Year
- KNDI N/A
- CGTX 2021
- Fundamental
- Price
- KNDI $1.22
- CGTX $1.82
- Analyst Decision
- KNDI
- CGTX Strong Buy
- Analyst Count
- KNDI 0
- CGTX 3
- Target Price
- KNDI N/A
- CGTX $2.83
- AVG Volume (30 Days)
- KNDI 124.0K
- CGTX 3.0M
- Earning Date
- KNDI 11-17-2025
- CGTX 11-12-2025
- Dividend Yield
- KNDI N/A
- CGTX N/A
- EPS Growth
- KNDI N/A
- CGTX N/A
- EPS
- KNDI N/A
- CGTX N/A
- Revenue
- KNDI $104,035,613.00
- CGTX N/A
- Revenue This Year
- KNDI N/A
- CGTX N/A
- Revenue Next Year
- KNDI N/A
- CGTX N/A
- P/E Ratio
- KNDI N/A
- CGTX N/A
- Revenue Growth
- KNDI N/A
- CGTX N/A
- 52 Week Low
- KNDI $0.89
- CGTX $0.22
- 52 Week High
- KNDI $1.81
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- KNDI 42.52
- CGTX 55.50
- Support Level
- KNDI $1.21
- CGTX $1.29
- Resistance Level
- KNDI $1.24
- CGTX $1.61
- Average True Range (ATR)
- KNDI 0.07
- CGTX 0.16
- MACD
- KNDI 0.00
- CGTX 0.04
- Stochastic Oscillator
- KNDI 40.48
- CGTX 72.56
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.